Yehia Hashad
Known title: EVP, R&D and CMOCIK: 0001877701
Associated companies
Transaction History
| BLCO | ▲ Buy | Grant | 20,973 | $0 | 8/5/2026 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 13,664 | $219K | 5/5/2026 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 5,075 | $93K | 2/27/2026 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 11,621 | $213K | 2/27/2026 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,169 | $40K | 2/26/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 35,046 | $0 | 2/25/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 29,406 | $0 | 2/18/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 17,715 | $0 | 8/5/2025 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,841 | $41K | 7/25/2025 | View on chart |
| BLCO | ▲ Buy | Grant | 25,225 | $0 | 2/26/2025 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,324 | $41K | 12/23/2024 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,751 | $49K | 12/23/2024 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,841 | $44K | 7/25/2024 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 2,143 | $35K | 3/1/2024 | View on chart |
| BLCO | ▲ Buy | Grant | 20,973 | $0 | 2/28/2024 | View on chart |
| BLCO | ▼ Sell | Tax Withholding | 3,996 | $79K | 7/25/2023 | View on chart |
| BLCO | ▲ Buy | Grant | 17,715 | $0 | 3/1/2023 | View on chart |
| BLCO | ▲ Buy | Grant | 35,000 | $0 | 7/25/2022 | View on chart |
| BLCO | ▲ Buy | Grant | 34,722 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.